Back to ARGXView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Active Idiopathic Inflammatory Myopathy
View Full LandscapeDrug Information
Target Indication
Active Idiopathic Inflammatory Myopathy
Clinical Trial
NCT05523167Last updated: 1/2/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
ARGX-113Phase 3
Pemphigus Vulgaris
Efgartigimod PH20 SCPhase 3
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
IVIG (Intravenous Immunoglobulin)Phase 3
Multifocal Motor Neuropathy (MMN)
EfgartigimodPhase 3
Postural Orthostatic Tachycardia Syndrome
Efgartigimod IVPhase 3
Generalized Myasthenia Gravis
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts